REMOVAL OF VIRULENCE FACTORS THROUGH EXTRACORPOREAL THERAPY

• US 20120305482A1
• Filed: 02/09/2011
• Published: 12/06/2012
• Est. Priority Date: 02/09/2010
• Status: Abandoned Application

• Current Assignee: ExThera Medical Corporation
• Original Assignee: Exthera AB
• Inventors: McCrea, Keith, Ward, Robert S.
• Application Number:
  US13/577,529
• Publication Number:
  US 20120305482A1
• Time in Patent Office: Days
• US Class Current: 210/638
• CPC Class Codes: A61K 31/727 Heparin; Heparan
• CPC Class Codes: A61M 1/362 changing physical properties of target cells by binding them to added particles to facilitate their subsequent separation from other cells, e.g. immunoaffinity
• CPC Class Codes: A61M 1/3679 by absorption A61M1/3675 takes precedence
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/08 Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock artificial tears A61P27/04

Abstract

A method to remove virulence factors from infected blood by passing the blood through a surface cartridge with immobilized carbohydrates, such as heparin, wherein the virulence factors are toxins released from pathogens such as B. anthracis, S. aureus, and P. aeruginosa.

Claims

1. A method for removal from mammalians blood of a pathogen or a toxin from said pathogen wherein said pathogen is a member selected from the group consisting of Bacillus anthracis, Pseudomonas aureginosa, and Staphylococcus aureus, said method comprising:

a. bringing a sample of blood in contact with a carbohydrate immobilized on a solid substrate, said carbohydrate having binding affinity for said pathogen or toxin, under conditions allowing the binding of said substrate to said pathogen or toxin in said sample of blood;

b. separating the sample from said substrate whereby said pathogen or said toxin is at least partially retained or said substrate and the removed sample has a reduced amount of said pathogen or toxin.

2. The method according to claim 1, wherein said pathogen is Bacillus anthracis.

3. The method according to claim 1, wherein said substrate has affinity to toxins that are capable of binding to heparin sulphate segments on syndecans.

4. The method according to claim 1, wherein said substrate has affinity to the protective antigen in anthrax toxin.

5. The method according to claim 1, wherein said solid substrate is comprised of at least one member selected from the group consisting of glass, cellulose, cellulose acetate, chitin, chitosan, crosslinked dextran, crosslinked agarose, polyurethane, polymethylmethacrylate, polyethylene or co-polymers of ethylene and other monomers, polyethylene imine, polypropylene, polysulfone, polyacrylonitrile, silicone and polyisobutylene.

6. The method according to claim 1, wherein said carbohydrate is heparin.

13. The method according to claim 2, wherein the bead comprises a polymer of polyethylene.

14. The method according to claim 2, wherein said beads have a diameter ranging from 100 and 450 microns.

15. The method of claim 14, wherein said beads have an average diameter of 0.3 mm.

16. The method according to claim 2, wherein the beads are coated with 0.5-10 mg heparin per gram of bead.

17. The method of claim 16, wherein the bead is coated with 2±

0.5 mg heparin per gram of bead.

18. The method according to claim 1, wherein the heparin has a mean molecular weight of about 8 kDa.

19. The method according to claim 1, wherein the heparin is attached to the bead by covalent end-point attachment.

20. The method according to claim 1, wherein said substrate binds to at least one member selected from the group consisting of anthrax lethal toxin, anthrax protective antigen, anthrax edema factor, anthrax lethal factor, anthrax polyglutamic acid capsule, anthralysin O, anthralysin B, S. aureus α

-toxin, S. aureus β

-toxin, and P. aureginosa Las A.

23. The method according to claim 1, wherein said method for removing a cytokine or pathogen is conducted in combination with at least one other extracorporeal treatment of said blood.

24. The method according to claim 23, wherein said at least one other extracorporeal treatment comprises at least one member selected from the group consisting of cardiopulmonary bypass (CPB), hemodialysis, and oxygenation.

7. A method for removing from blood at least one pathogen or toxin from said pathogen, wherein said pathogen is a member selected from the group consisting of Bacillus anthracis, Pseudomonas aureginosa, and Staphylococcus aureus, said method comprising:

causing a sample of blood or serum to flow over and past a high-surface-area solid substrate at a flow rate of ≧

50 ml/min wherein the surface of said solid substrate comprises heparin with a binding affinity for the pathogen or toxin, wherein said substrate is sufficiently nonporous such that adsorbents in the blood do not need to pass through pores in said substrate prior to adsorption, and wherein the size of the interstitial channel spaces between individual portions of said substrate and the amount of interstitial substrate surface area is such that when said flowing blood or serum in contact with said substrate at a flow rate of ≧

50 ml/min, said pathogen or toxin binds to said heparin to separate from said blood or serum and the transport of said blood or serum and adsorbents contained in it past said substrate is by means of convection transport more than Brownian diffusion transport.

8. The method according to claim 7, wherein said substrate comprises a packed column of non-porous rigid beads or particles, a column packed with a rigid reticulated foam, a column packed with a rigid monolith bed of sintered beads with internal flow channels, a column packed with woven or non woven rigid fabric, a column packed with a rigid yarn or an optionally hollow monofilament, a spiral wound cartridge, or a combination of at least two members selected from the group consisting of beads, rigid reticulated foam, sintered beads, fabric, yarn and monofilament.

9. The method according to claim 7 wherein the solid substrate comprises polyethylene beads coated with one or more polysaccharides.

10. The method according to claim 9 wherein at least one of said polysaccharides is selected from the group consisting of heparin, hyaluronic acid, salicylic acid, and chitosan

12. The method according to claim 7, wherein the flow rate of blood or serum ranges from about 150 and 2000 mL/minute.

11. A method for removing from blood at least one pathogen or toxin from said pathogen, wherein said pathogen is a member selected from the group consisting of Bacillus anthracis, Pseudomonas aureginosa, and Staphylococcus aureus, said method comprising:

causing a sample of blood to flow in contact with rigid polyethylene beads in a container at a flow rate of ≧

50 ml/min, wherein the surface of said beads comprises heparin with a binding affinity for the pathogen or toxin, wherein said beads are sufficiently rigid such that blood does not pass through pores in said substrate, and wherein the size of the interstitial channel spaces between individual ones of said beads and the amount of interstitial surface area of said beads is such that when said blood is in flow contact with said substrate at a flow rate of ≧

50 ml/min, said pathogen or toxin binds to said heparin to separate from said blood and the flow transport of said blood past said substrate is by means of convection transport more than Brownian diffusion transport method.

21. A method of treating anthrax in a mammal in need of such treatment, comprising:

a) bringing a sample of blood from a mammal into flow contact with a solid substrate comprising with rigid polyethylene beads in a container at a flow rate of at least about 150 ml/min, wherein the surface of said beads comprises heparin with a binding affinity for Bacillus anthracis or a toxin therefrom, wherein said beads are sufficiently rigid such that blood does not pass through pores in said substrate, and wherein the size of the interstitial channel spaces between individual ones of said beads and the amount of interstitial surface area of said beads is such that when said blood is in flow contact with said substrate at a flow rate of at least about 150 ml/min, said Bacillus anthracis or said toxin binds to said heparin to separate from said blood and the flow transport of said blood past said substrate is by means of convection transport more than Brownian diffusion transport method;

b) separating the blood from the solid substrate.

22. The method according to claim 21, wherein the blood is taken from and returned to the same mammal.